About EryDel
EryDel is a Technology company based in Milan (Italy) founded in 2007 by Giovanni Mambrini, and was acquired by Quince Therapeutics in July 2023. Erythrocyte encapsulation systems for drug delivery are developed. It operates in the Technology and Healthcare sectors. EryDel has raised $31.7 million across 3 funding rounds from investors including Quince Therapeutics, European Union and Genextra. EryDel offers products and services including eDSP and AIDE Platform. Its focus areas include Life Sciences, Drug Delivery, Diversified and High Tech. Its legal entity is Quince Therapeutics, Inc.
Company details
EryDel was founded in 2007 in Milan, Italy, focusing on biotechnology and drug delivery innovations. Operations center on the proprietary red cell loader (RCL) device and erykit, which enable loading of small molecules, proteins, and enzymes into human red blood cells. Therapeutics in the pipeline include erdex, advanced to phase 3 clinical trials, and eetm, completed through phase 2.
- Headquarters Milan, Italy
- Founders Giovanni Mambrini
- Stage Acquired
- SectorsTechnologyHealthcare
- Email••••••••
- Phone•••• ••••
- Website erydel.com
- Social LinkedIn X Facebook YouTube
- Acquired by Quince Therapeutics (Jul 2023)
- Legal Name Quince Therapeutics, Inc.
- Total Equity Funding$31.7M (USD)
in 3 rounds
- Latest Funding Round$31.7M (USD), Series B
Apr 2018
- InvestorsQuince Therapeutics
& 5 more
- Acquired byQuince Therapeutics
(Jul 2023)
Products & Services of EryDel
EryDel offers a comprehensive portfolio of products and services, including eDSP and AIDE Platform.
Encapsulated dexamethasone for treating Ataxia-Telangiectasia in patients.
Technology platform for encapsulating drugs into red blood cells.
Apps and channels of EryDel
its YouTube channel Quince Therapeutics has 52 subscribers and 7 videos.
Videos from EryDel
The most watched videos on EryDel's YouTube channel, Quince Therapeutics (52 subscribers). Click a video to play it here.
More on Quince Therapeutics.
Funding Insights of EryDel
EryDel has successfully raised a total of $31.7M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $31.7 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $31.7M
- Total Rounds 3
- Last Round Series B — $31.7M
- Investors Count 5
All 3 funding rounds of EryDel with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2018 | $31.7M | Series B | – | Sofinnova Partners | |
| Jan 2016 | $4.7M | Grant | – | – | |
| Jul 2013 | Series B | – | Genextra |
6 investors in total: 6 institutional.
Investors in EryDel
EryDel has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Quince Therapeutics, European Union and Genextra.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A holding company focused on life science investments is operated. | genextra.it | Milan, Italy | ||
VC firm investing in seed and early stage companies in Italy | innogestcapital.com | Milan, Italy | ||
| focussgr.it | ||||
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Therapeutics for orthopedic diseases are developed and advanced. | 2012 | quincetx.com | San Francisco, United States |
Investor details for EryDel
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EryDel
1 people are tracked at EryDel (1 in leadership).
| Name | Role | Group |
|---|---|---|
Giovanni Mambrini | Co-Founder & COO | Leadership |
Complete people profiles for EryDel
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of EryDel
4 dated milestones of EryDel across 16 years, from founding to its latest funding, stage changes and deals.
- Founded EryDel is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $31.7M.
- Exit Acquired by Quince Therapeutics.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Erydel
Complete news archive for EryDel
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EryDel
EryDel was founded in 2007 and raised its 1st funding round 6 years after it was founded.
EryDel is headquartered in Milan, Italy. It is registered at Milan, Lombardy, Italy.
EryDel is a funded company, having raised a total of $31.7M across 3 funding rounds to date.
EryDel was founded in 2007 in Milan, Italy, focusing on biotechnology and drug delivery innovations. Operations center on the proprietary red cell loader (RCL) device and erykit, which enable loading of small molecules, proteins, and enzymes into human red blood cells. Therapeutics in the pipeline include erdex, advanced to phase 3 clinical trials, and eetm, completed through phase 2.
EryDel offers eDSP and AIDE Platform.
EryDel has 6 investors. Key investors include Quince Therapeutics, European Union, Genextra, Innogest Capital, and Focus Gestioni SGR.
EryDel operates through Quince Therapeutics, Inc..
Yes. EryDel was acquired by Quince Therapeutics in July 2023.